Word abonnee en neem Beursduivel Premium
Rode planeet als pijlen grid met hoorntjes Beursduivel

AVA 2019

15 Posts
| Omlaag ↓
  1. [verwijderd] 19 april 2019 11:13
    hi Tom, vandaag onder het mes...als de operatie zonder complicaties verloopt dan zal ik tegen die tijd toch wel hersteld zijn en absoluut van de partij.

    groet ivet
  2. forum rang 6 Tom3 21 mei 2019 20:18
    Zo dat was het dan weer voor dit jaar. In september weten we meer over Usher, kreeg de indruk dat men dit echt geheim wil houden. Maar gezien het aantal aandelen/opties dat het management zich heeft toebedeeld heeft men er alle vertrouwen in. Een lage uitoefenprijs (tgv de lage beurskoers) is natuurlijk ook niet verkeerd voor de heren/dame ontvangers. Wel een tegenslag was dat de samenwerking met Galapagos beëindigd is zonder resultaat en dat het Axiomer platform nog bewezen moet worden. Momenteel wordt Axiomer wel ingezet voor een nog te ontwikkelen rna medicijn. We gaan het zien.
  3. [verwijderd] 22 mei 2019 12:20
    HI Tom.. i didnt come to the annual meeting this year.. bummer .
    so they said the collaboration w Galapagos ended? they may have to
    update their site as it is listed . www.proqr.com/pipeline/

    other than this revelation is there anything else interesting you could
    share?

    thanks
  4. forum rang 6 Tom3 23 mei 2019 08:33
    quote:

    joel12 schreef op 22 mei 2019 12:21:

    what i find sort of interesting from the pipeline page www.proqr.com/pipeline/

    is that the cystic fibrosis product was completely removed.

    did they talk about this?
    Yes: too much competition for CF. The Huntington research will be paid by third parties (like DEB).
  5. [verwijderd] 23 mei 2019 14:42
    ok ya makes sense. for CF i cant imagine they are not planning to partner that out. cant imagine, about a year ago in a presentation the ceo said that many dont understand how valuable it is.
    but I had a question about Galapagos .. what is the status of the collaboration there? thanks Tom!
    btw, the Usher trial and results look promising, at least Proqr it is .. and next month is sponsoring an USHER event. around that time also presents at jmp just fyi.

    how where the spirits etc at the meeting?
  6. forum rang 6 Tom3 23 mei 2019 18:48
    quote:

    joel12 schreef op 23 mei 2019 14:42:

    ok ya makes sense. for CF i cant imagine they are not planning to partner that out. cant imagine, about a year ago in a presentation the ceo said that many dont understand how valuable it is.
    but I had a question about Galapagos .. what is the status of the collaboration there? thanks Tom!
    btw, the Usher trial and results look promising, at least Proqr it is .. and next month is sponsoring an USHER event. around that time also presents at jmp just fyi.

    how where the spirits etc at the meeting?
    Thanks for the Usher info. I assume this is in the US (will you attend this?). The collaboration with Galapagos has been terminated, no match?. Currently Axiomer is tested in 1 eye disease (pre-clinical research). News to be expected in 2020. Well officially the Usher trial is double blinded and only a very few seem to be informed. Rodman and Platenburg were in NY. So I have seen only poker faces. De Boer was so kind to admit that all patients in the LCA phase 1 trial have opted for treatment of their other eye: so this is a success. The fact that an Alnylam manager has been appointed in the board points to at least a decent future. I can`t imagine that she wants to join a company that is under too much stress. The second new board member is the present CFO from Galapagos. Interesting in case of a new secondary offering I would say.
  7. forum rang 6 Tom3 25 mei 2019 13:06
    quote:

    joel12 schreef op 24 mei 2019 19:04:

    ya the usher is in the US www.usher-syndrome.org/ush2019/progra...

    so you say that the collaboration w galapagos has been terminated? they said it or you think it has?

    thanks.. if you think of anything else interesting let me know.. btw proqr will be at JMP mid june to present.
    Wow, the Usher day(-s) in July is an important event for ProQR. By then the main findings from the ongoing trial should be known. Are you involved too in this terrible disease? Yes the termination has been communicated on the shareholders meeting. The final prove of Axiomer will not be delivered in 2019. Focus is on the rapid commercialization of the eye disease franchise as has been laid out in the winter. If this pans out as promised this stock could soar again.
  8. [verwijderd] 12 juni 2019 13:33
    quote:

    joel12 schreef op 24 mei 2019 19:04:

    ya the usher is in the US www.usher-syndrome.org/ush2019/progra...

    so you say that the collaboration w galapagos has been terminated? they said it or you think it has?

    thanks.. if you think of anything else interesting let me know.. btw proqr will be at JMP mid june to present.
    Dit event lijkt me nu de uitgelezen plek om de resultaten van Stellar te bespreken en te doorgronden. Die worden "mid 2019" bekend gemaakt. Ik neem aan dat intern de resultaten nu wel duidelijk zijn. Dus laten we zeggen ergens begin juli het persbericht met goede resultaten? Of zouden ze daar als silver sponsor gaan staan zonder resultaten of met slechte resultaten?
15 Posts
|Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beursduivel.be

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.160
AB InBev 2 5.544
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 52.502
ABO-Group 1 25
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 267
Accsys Technologies 23 10.931
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 193
Adecco 1 1
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.892
Aedifica 3 927
Aegon 3.258 323.211
AFC Ajax 538 7.093
Affimed NV 2 6.306
ageas 5.844 109.909
Agfa-Gevaert 14 2.074
Ahold 3.538 74.360
Air France - KLM 1.025 35.329
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.065
Alfen 16 25.500
Allfunds Group 4 1.525
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 426
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.826
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 244.242
AMG 972 134.747
AMS 3 73
Amsterdam Commodities 305 6.754
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 501
Antonov 22.632 153.605
Aperam 92 15.104
Apollo Alternative Assets 1 17
Apple 5 387
Arcadis 252 8.808
Arcelor Mittal 2.035 321.086
Archos 1 1
Arcona Property Fund 1 287
arGEN-X 17 10.379
Aroundtown SA 1 221
Arrowhead Research 5 9.758
Ascencio 1 30
ASIT biotech 2 697
ASMI 4.108 39.697
ASML 1.767 112.166
ASR Nederland 21 4.522
ATAI Life Sciences 1 7
Atenor Group 1 523
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 14.342
Axsome Therapeutics 1 177
Azelis Group 1 67
Azerion 7 3.463

Macro & Bedrijfsagenda

  1. 11 april

    1. Faillissementen, maart (NL)
    2. Inflatie, maart (Dld)
    3. Industriële productie, februari (VK)
    4. Handelsbalans, februari (VK)
    5. Ahold Delhaize ex-dividend €0,67
    6. SBM Offshore ex-dividend €0,8606
    7. JPMorgan Chase, cijfers eerste kwartaal
    8. Morgan Stanley, cijfers eerste kwartaal
    9. Wells Fargo, cijfers eerste kwartaal
    10. BlackRock, cijfers eerste kwartaal
de volitaliteit verwacht indicator betekend: Market moving event/hoge(re) volatiliteit verwacht